IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2025 10-K Annual Report
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
IOVANCE BIOTHERAPEUTICS, INC. FY2025 10-K Analysis
Business Overview
- • Core business: Commercial-stage biopharma pioneering individualized tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers
- • New/regulatory: Amtagvi approved in U.S. and Canada, pending UK/Australia 2026 approvals, withdrawn and resubmitting EU MAA in 2026
- • Strategic shift: Transitioned all Amtagvi/lifileucel manufacturing in-house at FDA-approved iCTC facility, ending contract manufacturing early 2026
- • Quantitative highlight: Over 1,500 patients treated with commercial/investigational TIL therapies; iCTC capacity >5,000 patients annually
- • Noteworthy fact: Presented first real-world Amtagvi data (44% ORR) in 2026; advancing Phase 3 TILVANCE-301 trial combining lifileucel with pembrolizumab in frontline melanoma
Management Discussion & Analysis
- • Revenue $263.5M, up 61% YoY; Amtagvi $220.0M (up $116.5M), Proleukin $43.5M (down $17.0M)
- • Cost of sales $173.2M, up 86%; R&D $300.3M, up 9%; SG&A flat at $152.3M; total expenses $666.9M, up 19%
- • Best performing segment: Amtagvi revenue $220.0M, worst: Proleukin revenue down 28% to $43.5M
- • No explicit cash flow, buybacks, dividends data provided; capex details not disclosed
- • Outlook: expect European MAA resubmission in 2026; ongoing clinical trials in multiple indications; focus on global commercial expansion and manufacturing optimization
Risk Factors
- • Cybersecurity risk from internal systems and CROs, requiring increased resources to counter sophisticated threats
- • Dependency on IT infrastructure vulnerable to security breaches impacting business operations
- • Audit Committee oversight on internal controls risks related to cybersecurity threats
- • Management led by VP, Infrastructure and Security with professional cybersecurity certifications tasked with risk management
- • External cybersecurity consultants employed alongside internal team for enhanced protection measures
IOVANCE BIOTHERAPEUTICS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$264M
▲ +60.6% YoY
Net Income
-$391M
▼ -5.1% YoY
Operating Margin
-153.1%
▲ +8785bp YoY
Net Margin
-148.4%
▲ +7846bp YoY
ROE
-56.0%
▼ -358bp YoY
Total Assets
$913M
▲ +0.3% YoY
EPS (Diluted)
$-1.09
▲ +14.8% YoY
Operating Cash Flow
-$302M
▲ +14.3% YoY
Source: XBRL data from IOVANCE BIOTHERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on IOVANCE BIOTHERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.